Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display & Cocktail

23P - Novel ERα degrader, 3,20(R)-dihydroxy-19-norpregnatriene, inhibits MCF-7 cell growth through p21/CDK2/CDK4 pathway


02 Mar 2020


Poster Display & Cocktail


Alexander Scherbakov


Annals of Oncology (2020) 31 (suppl_1): S10-S13. 10.1016/annonc/annonc85


A.M. Scherbakov1, I.S. Levina2, Y. Kuznetsov2, M. Tserfas2, I. Zavarzin2

Author affiliations

  • 1 Oncoproteomics Laboratory, N.N. Blokhin National Medical Research Center of Oncology, 115522 - Moscow/RU
  • 2 N.D. Zelinsky Institute of Organic Chemistry, 119991 - Moscow/RU


Abstract 23P

Breast cancer is the most common cancer in women. There is an urgent need for new drugs with novel modes of effect on tumors. It is very important to develop compounds with high activity against tumor cells and low toxicity on normal epithelium. The development of new anti-tumor drugs based on steroidal compounds is a promising approach for obtaining agents that combine antiestrogenic, cytostatic and proapoptotic effects. The aim of the work is to study the mechanism of anticancer action of new steroidal compound, 3,20 (R)-dihydroxy-19-norpregnatriene (Kuz7).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.